Luis Peña Icart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luis Peña Icart has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Celimar Sinézia
Laboratório de Biotecnologia e Bioengenharia Tecidual, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CCS, Rio de Janeiro 21941-902, RJ, Brazil
2 shared publications - Luis Mauricio T. R. Lima
Universidade Federal do Rio de Janeiro
2 shared publications - Tháyna Sisnande
Laboratório de Biotecnologia Farmacêutica (pbiotech), Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil; Programa de Pós-Graduação em Química Biológica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil
2 shared publications - Cristiane Gimenes de Souza
Petroleum and Biofuels Chemistry Program PRH 20.1, Instituto de Química, Universidade Federal do Rio de Janeiro, Cidade Universitária, Brasil
1 shared publication - Dionisio Zaldivar Silva
USST-UH International Joint Laboratory for Tumor Diagnosis and Energy Treatment, University of Shanghai for Science and Technology, Shanghai 200093, China
1 shared publication - Edson Rodrigo Fernandes dos Santos
Centro de Tecnologia, COPPE, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
1 shared publication
Latest Publications
- 31 January 2024
- Published by Wiley in Peptide Science
- Vol. 116 (4)
Oral delivery of the amylin receptor agonist pramlintide
Amylin receptor agonism safely benefit diabetic patients, reducing the insulin requirements and glycemic excursions. Pramlintide is the triple proline human amylin analogue first used as injectable drug, but lacking physico‐chemical compatibility when co‐formulated with insulin. Here, we report the design and characterization of polymeric microparticles for oral delivery of pramlintide. Eudragit S100, a gastric‐resistant polymer, was used in preparation of pramlintide‐loaded spherical microcapsules by double emulsion and solvent evaporation technique, with approximately 66 μm ± 11 particle size, with 83.2% ± 2.7 efficiency for pramlintide entrapment and 67.6% ± 2.1 yield. Intra‐venous pramlintide free in solution showed a plasmatic half‐life of 6.8 min in mice. In contrast, oral delivery of acid‐resistant pramlintide‐loaded microparticles in mice showed a protracted release for 120 min compared to 30 min obtained for pramlintide in solution. Our data provide evidences for the potential use of the oral route in the therapeutic development of pramlintide formulations.
- 31 January 2024
- Published by Wiley in Peptide Science
- Vol. 116 (4)
Oral delivery of the amylin receptor agonist pramlintide
Amylin receptor agonism safely benefit diabetic patients, reducing the insulin requirements and glycemic excursions. Pramlintide is the triple proline human amylin analogue first used as injectable drug, but lacking physico‐chemical compatibility when co‐formulated with insulin. Here, we report the design and characterization of polymeric microparticles for oral delivery of pramlintide. Eudragit S100, a gastric‐resistant polymer, was used in preparation of pramlintide‐loaded spherical microcapsules by double emulsion and solvent evaporation technique, with approximately 66 μm ± 11 particle size, with 83.2% ± 2.7 efficiency for pramlintide entrapment and 67.6% ± 2.1 yield. Intra‐venous pramlintide free in solution showed a plasmatic half‐life of 6.8 min in mice. In contrast, oral delivery of acid‐resistant pramlintide‐loaded microparticles in mice showed a protracted release for 120 min compared to 30 min obtained for pramlintide in solution. Our data provide evidences for the potential use of the oral route in the therapeutic development of pramlintide formulations.
- Open Access
Oral delivery of the amylin receptor agonist pramlintide
Aim The aims of this study were to design and characterize polymeric microparticles for oral delivery of pramlintide, a triple proline human amylin analogue clinically proved efficient in diabetes therapy. Methods The microparticles were prepared with gastric-resistant polymer Eudragit S100 by double-emulsion and solvent evaporation technique. The study responses were repeatability, encapsulation efficiency, yield, morphology, particle size, response to acidic and alkaline milieu and pharmacokinetics. Results We obtained spherical microcapsules, with particle size of 66 μm ± 11, with 83.2 % ± 2.7 efficiency for pramlintide entrapment and 67.6 % ± 2.1 yield. Intra-venous pramlintide free in solution showed a plasmatic half-life of 6.8 min in mice. In contrast, oral delivery of acid-resistant pramlintide-loaded microparticles in mice showed a protracted release for 120 min compared to 30 min obtained for pramlintide in solution. Conclusions Oral route is an alternative for therapeutic development of pramlintide formulations.
Open AccessOral delivery of the amylin receptor agonist pramlintide
Aim The aims of this study were to design and characterize polymeric microparticles for oral delivery of pramlintide, a triple proline human amylin analogue clinically proved efficient in diabetes therapy. Methods The microparticles were prepared with gastric-resistant polymer Eudragit S100 by double-emulsion and solvent evaporation technique. The study responses were repeatability, encapsulation efficiency, yield, morphology, particle size, response to acidic and alkaline milieu and pharmacokinetics. Results We obtained spherical microcapsules, with particle size of 66 μm ± 11, with 83.2 % ± 2.7 efficiency for pramlintide entrapment and 67.6 % ± 2.1 yield. Intra-venous pramlintide free in solution showed a plasmatic half-life of 6.8 min in mice. In contrast, oral delivery of acid-resistant pramlintide-loaded microparticles in mice showed a protracted release for 120 min compared to 30 min obtained for pramlintide in solution. Conclusions Oral route is an alternative for therapeutic development of pramlintide formulations.
- 1 April 2023
- Published by Bentham Science Publishers Ltd. in Current Applied Polymer Science
- Vol. 6 (1) , 14-25
Modified Asparaginase for Treatment of Cancer Historical Appraisal and Future Perspectives
Asparaginase (ASNase) is widely used as an important component of first-line treatment for acute lymphoblastic leukemia (ALL). Although it is associated with a high rate of complete remission (~93%), challenges remain due to several side effects ranging from immune reactions to severe toxicity, largely associated with its higher immunogenicity and glutamine coactivity. Innovative products have therefore been devised to minimise these adverse reactions while increasing the enzymes’ pharmacokinetic properties, stability, and efficacy. This review focuses on commercially available formulations and others that remain in development, discussing the most recent strategies for preparing alternative formulations of the enzyme to be less immunogenic and have low glutaminase coactivity by using site-specific mutagenesis, PEGylation, and encapsulation techniques.
- 1 April 2023
- Published by Bentham Science Publishers Ltd. in Current Applied Polymer Science
- Vol. 6 (1) , 14-25
Modified Asparaginase for Treatment of Cancer Historical Appraisal and Future Perspectives
Asparaginase (ASNase) is widely used as an important component of first-line treatment for acute lymphoblastic leukemia (ALL). Although it is associated with a high rate of complete remission (~93%), challenges remain due to several side effects ranging from immune reactions to severe toxicity, largely associated with its higher immunogenicity and glutamine coactivity. Innovative products have therefore been devised to minimise these adverse reactions while increasing the enzymes’ pharmacokinetic properties, stability, and efficacy. This review focuses on commercially available formulations and others that remain in development, discussing the most recent strategies for preparing alternative formulations of the enzyme to be less immunogenic and have low glutaminase coactivity by using site-specific mutagenesis, PEGylation, and encapsulation techniques.
- 13 October 2017
- Published by Taylor & Francis in International Journal of Polymeric Materials and Polymeric Biomaterials
- Vol. 67 (13) , 776-782
Paclitaxel-loaded PLA/PEG/fluorescein anticancer agent prepared by Ugi reaction
- 13 October 2017
- Published by Taylor & Francis in International Journal of Polymeric Materials and Polymeric Biomaterials
- Vol. 67 (13) , 776-782
Paclitaxel-loaded PLA/PEG/fluorescein anticancer agent prepared by Ugi reaction